Get the Stockscreener App
9.58
0.10%
-0.010
Atara Biotherapeutics Inc stock is traded at $9.58, with a volume of 225.23K.
It is down -0.10% in the last 24 hours and up +82.82% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$9.59
Open:
$9.71
24h Volume:
225.23K
Relative Volume:
0.16
Market Cap:
$81.55M
Revenue:
$120.77M
Net Income/Loss:
$32.69M
P/E Ratio:
3.2869
EPS:
2.9146
Net Cash Flow:
$-50.94M
1W Performance:
+14.87%
1M Performance:
+82.82%
6M Performance:
-30.38%
1Y Performance:
+25.89%
1-Day Range:
$8.65
$9.8051
1-Week Range:
$7.90
$10.80
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.58 | 81.63M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. - GlobeNewswire
Redmile funds disclose 9.9% Atara Biotherapeutics (ATRA) stake via warrants cap - Stock Titan
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, - GlobeNewswire
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Manufacturing and Supply-Chain Risks Threaten Atara Biotherapeutics’ Cell Therapy Pipeline - TipRanks
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com
8-K: Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progressmoomoo - Moomoo
Atara Biotherapeutics | 424B5: Prospectus - Moomoo
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - The National Law Review
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Adage and principals report 8.56% stake in Atara (NASDAQ: ATRA) - Stock Titan
Atara Biotherapeutics: Runway Into Mid-2027 >ATRA - Moomoo
Atara Biotherapeutics (ATRA) Eps Diluted (TTM) - Zacks Investment Research
Atara (ATRA) Provides Update on BLA Resubmission and Financial S - GuruFocus
Atara Biotherapeutics 1Q Loss/Shr 29c >ATRA - Moomoo
Atara BiotherapeuticsMay Offer Up To $79.27 Million In Common Stock As Of May 12, 2026SEC Filing - TradingView
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Dead - GuruFocus
Atara Biotherapeutics: Q1 Earnings Snapshot - WKYC
FinancialContentPomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - FinancialContent
Atara Biotherapeutics (NASDAQ: ATRA) adds $79.27M to ATM sales agreement - Stock Titan
[10-Q] Atara Biotherapeutics, Inc. Quarterly Earnings Report - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) Q1 2026 loss and cash runway update - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Atara Biotherapeutics | SCHEDULE 13D/A: Others - Moomoo
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Atara Biotherapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Barchart.com
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Atara Biotherapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
MSN Money - MSN
Atara Biotherapeutics | 3: Initial statement of beneficial ownership of securities- EcoR1 Capital, LLC - Moomoo
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara biotherapeutics director James Huang sells $3.16m in stock By Investing.com - Investing.com Australia
Atara biotherapeutics director James Huang sells $3.16m in stock - Investing.com
Panacea funds cut Atara (ATRA) stake but remain 16.1% holder - Stock Titan
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Panacea Innovation Ltdmoomoo - Moomoo
Panacea funds linked to Atara (NASDAQ: ATRA) director sell 313,446 shares - Stock Titan
EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock By Investing.com - Investing.com South Africa
EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock - Investing.com
EcoR1 Capital (NASDAQ: ATRA) adds 507K Atara shares in open-market buy - Stock Titan
EcoR1 Capital (NASDAQ: ATRA) reports initial 1.04M-share Atara stake - Stock Titan
Atara Biotherapeutics, Inc. Sued for Securities Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Atara Biotherapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA Stockholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 07 '26 |
Buy |
9.35 |
507,407 |
4,744,255 |
1,552,000 |
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):